Effectiveness of First-line Therapy for Small Cell Lung Cancer with IO Chemotherapy

被引：0
|
作者：
Grohe, C. [1 ]
机构：
[1] Elk Ev Lungenklin, Klin Pneumol, Berlin, Germany
来源：
PNEUMOLOGIE | 2022年 / 76卷
关键词：
D O I：
10.1055/s-0042-1747799
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Po 249
引用
收藏
页码：S49 / S49
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC).
    Kim, Ashley
    Devine, Beth
    Roth, Joshua A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
    Li Ling-Yu
    Wang Hong
    Chen Xiao
    Li Wen-Qian
    Cui Jiu-Wei
    中华医学杂志英文版, 2019, 132 (23) : 2790 - 2794
  • [43] Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China
    Lu, Shun
    Yu, Yongfeng
    Fu, Shijun
    Ren, Hongye
    PLOS ONE, 2018, 13 (10):
  • [44] Cost-effectiveness of adding serplulimab to first-line chemotherapy for extensive-stage small-cell lung cancer in China
    Kang, Shuo
    Liu, Huanlong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (09) : 1081 - 1088
  • [45] Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
    Ding, Dong
    Hu, Huabin
    Li, Shuosha
    Zhu, Youwen
    Shi, Yin
    Liao, Mengting
    Liu, Jin
    Tian, Xu
    Liu, Aiting
    Huang, Jin
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (10): : 1141 - +
  • [46] First-line atezolizumab plus chemotherapy in treatment of extensive small cell lung cancer: a cost-effectiveness analysis from China
    Li, Ling-Yu
    Wang, Hong
    Chen, Xiao
    Li, Wen-Qian
    Cui, Jiu-Wei
    CHINESE MEDICAL JOURNAL, 2019, 132 (23) : 2790 - 2794
  • [47] Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy
    Hao, Zhonglin
    Veedu, Janeesh Sekkath
    CLINICAL LUNG CANCER, 2022, 23 (01) : 14 - 20
  • [48] Docetaxel as a single agent in first-line therapy of non-small cell lung cancer
    Rosell, R
    ONKOLOGIE, 2000, 23 : 16 - 17
  • [49] Systemic therapy options following first-line chemoimmunotherapy in small-cell lung cancer
    Pacheco, Jose M.
    JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 6264 - 6274
  • [50] Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer
    Hayashi, H.
    Okamoto, I.
    Morita, S.
    Taguri, M.
    Nakagawa, K.
    ANNALS OF ONCOLOGY, 2012, 23 (06) : 1537 - 1541
12345